Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Futura Medical ( (GB:FUM) ) has provided an update.
Futura Medical plc has noted a recent increase in its share price, which the board attributes to no specific reason other than recent board changes and the proposed appointment of Alex Duggan as Interim CEO. The company continues to focus on its core strength in developing clinically proven sexual health products, with Eroxon® being a key product that addresses unmet needs in the ED market. This development could further solidify Futura’s position in the sexual health industry, potentially impacting stakeholders positively.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and commercialization of innovative sexual health products. Their primary offerings include Eroxon®, a topical gel for erectile dysfunction (ED), and other products like WSD4000 and Eroxon® Intense. The company focuses on addressing significant unmet needs in the sexual health market, with distribution partners in major markets such as the US and Europe.
Average Trading Volume: 599,736
Technical Sentiment Signal: Sell
Current Market Cap: £23.9M
For detailed information about FUM stock, go to TipRanks’ Stock Analysis page.